Lundbeck_subbed.qxp 6/8/09 10:06 Page 38
disorders and use of cardiovascular procedures after Psychiatry, 2000;61:742–9. disease: current knowledge and future directions for
myocardial infarction, JAMA, 2000;283:506–11. 77. Koro CE, Fedder DO, L’Italien GJ, et al., An assessment of research on risk factors, Circulation, 1998;97:1095–1102.
54. Newcomer JW, Second-generation (atypical) the independent effects of olanzapine and risperidone 98. Rich-Edwards JW, Manson JE, Hennekens CH, et al., The
antipsychotics and metabolic effects: a comprehensive exposure on the risk of hyperlipidemia in schizophrenic primary prevention of coronary heart disease in women, N
literature review, CNS Drugs, 2005;19(Suppl. 1):1–93. patients, Arch Gen Psychiatry, 2002;59:1021–6. Engl J Med, 1995;332:1758–66.
55. Grundy SM, Cleeman JI, Daniels SR, et al., Diagnosis and 78. Haupt DW, Fahnestock PA, Flavin KA, et al., Adiposity and 99. Bassuk SS, Manson JE, Epidemiological evidence for the
management of the metabolic syndrome, Circulation, insulin sensitivity derived from intravenous glucose role of physical activity in reducing risk of type 2 diabetes
2005;112:2735–52. tolerance tests in antipsychotic-treated patients, and cardiovascular disease, J Appl Physiol, 2005;99:
56. Calle EE, Thun MJ, Petrelli JM, et al., Body-mass index and Neuropsychopharmacology, 2007;32:2561–9. 1193–1204.
mortality in a prospective cohort of US adults, N Engl J Med, 79. Newcomer JW, Haupt DW, Fucetola R, et al., Abnormalities 100.Agid O, Kapur S, Arenovich T, et al., Delayed-onset
1999;341:1097–1105. in glucose regulation during antipsychotic treatment of hypothesis of antipsychotic action: a hypothesis tested
57. Willett WC, Dietz WH, Colditz GA, Guidelines for healthy schizophrenia, Arch Gen Psychiatry, 2002;59:337–45. and rejected, Arch Gen Psychiatry, 2003;60:1228–35.
weight, N Engl J Med, 1999;341:427–34. 80. Henderson DC, Cagliero E, Copeland PM, et al., Glucose 101.Agid O, Seeman P, Kapur S, The ‘delayed onset’ of
58. Haffner SM, Lehto S, Ronnemaa T, et al., Mortality from metabolism in patients with schizophrenia treated with antipsychotic action – an idea whose time has come and
coronary heart disease in subjects with type 2 diabetes atypical antipsychotic agents: a frequently sampled gone, J Psychiatry Neurosci, 2006;31:93–100.
and in nondiabetic subjects with and without prior intravenous glucose tolerance test and minimal model 102.Leucht S, Busch R, Hamann J, et al., Early-onset
myocardial infarction, N Engl J Med, 1998;339:229–34. analysis, Arch Gen Psychiatry, 2005;62:19–28. hypothesis of antipsychotic drug action: a hypothesis
59. Kahn R, Buse J, Ferrannini E, et al., The metabolic 81. Bergman RN, Ader M, Atypical antipsychotics and glucose tested, confirmed and extended, Biol Psychiatry, 2005;57:
syndrome: time for a critical appraisal. Joint statement homeostasis, J Clin Psychiatry, 2005;66:504–14. 1543–9.
from the American Diabetes Association and the 82. Houseknecht KL, Robertson AS, Zavadoski W, et al., Acute 103.Kapur S, Arenovich T, Agid O, et al., Evidence for onset of
European Association for the Study of Diabetes, effects of atypical antipsychotics on whole-body insulin antipsychotic effects within the first 24 hours of
Diabetologia, 2005;48:1684–99. resistance in rats: implications for adverse metabolic treatment, Am J Psychiatry, 2005;162:939–46.
60. McEvoy JP, Meyer JM, Goff DC, et al., Prevalence of the effects, Neuropsychopharmacology, 2007;32:289–97. 104.Agid O, Kapur S, Warrington L, et al., Early onset of
metabolic syndrome in patients with schizophrenia: 83. Ulcickas Yood M, deLorenze G, Quesenberry C, Jr, et al., antipsychotic response in the treatment of acutely
baseline results from the Clinical Antipsychotic Trials of Incidence of diabetes in atypical antipsychotic users agitated patients with psychotic disorders, Schizophr Res,
Intervention Effectiveness (CATIE) schizophrenia trial and differs according to agent: multisite epidemiologic 2008;102:241–8.
comparison with national estimates from NHANES III, study results, Eur Neuropsychopharmacol, 2008;118 105.Raedler TJ, Schreiner A, Naber D, et al., Early onset of
Schizophr Res, 2005;80:19–32. (Suppl. 4):S401. treatment effects with oral risperidone, BMC Psychiatry,
61. De Hert M, Schreurs V, Sweers K, et al., Typical and 84. Montanez A, Ruskin JN, Hebert PR, et al., Prolonged QTc 2007;7:4.
atypical antipsychotics differentially affect long-term interval and risks of total and cardiovascular mortality and 106.Agid O, Mamo D, Ginovart N, et al., Striatal vs extrastriatal
incidence rates of the metabolic syndrome in sudden death in the general population: a review and dopamine D2 receptors in antipsychotic response,
first-episode patients with schizophrenia: a retrospective qualitative overview of the prospective cohort studies, Neuropsychopharmacology, 2007;32:1209–15.
chart review, Schizophr Res, 2008;101:295–303. Arch Intern Med, 2004;164:943–8. 107.Nordstrom AL, Farde L, Halldin C, Time course of
62. De Hert M, 2009; in press. 85. Bednar MM, Harrigan EP, Anziano RJ, et al., The QT D2-dopamine receptor occupancy examined by PET after
63. Newcomer JW, Haupt DW, The metabolic effects of interval, Prog Cardiovasc Dis, 2001;43:1–45. single oral doses of haloperidol, Psychopharmacology (Berl),
antipsychotic medications, Can J Psychiatry, 2006;51:480–91. 86. Committee for Proprietary Medicinal Products, The 1992;106:433–8.
64. Meyer JM, Effects of atypical antipsychotics on weight and assessment of the potential for QT interval prolongation 108.Tauscher-Wisniewski S, Kapur S, Tauscher J, et al.,
serum lipid levels, J Clin Psychiatry, 2001;62:27–34. by non-cardiovascular medicinal products, London: Quetiapine: an effective antipsychotic in first-episode
65. Henderson DC, Cagliero E, Gray C, et al., Clozapine, Committee for Proprietary Medicinal Products, 1997. schizophrenia despite only transiently high dopamine-2
diabetes mellitus, weight gain, and lipid abnormalities: A 87. Gupta A, Lawrence AT, Krishnan K, et al., Current concepts receptor blockade, J Clin Psychiatry, 2002;63:992–7.
five-year naturalistic study, Am J Psychiatry, 2000;157: in the mechanisms and management of drug-induced QT 109.Bartko G, Herczeg I, Bekesy M, Predicting outcome of
975–81. prolongation and torsade de pointes, Am Heart J, 2007;153: neuroleptic treatment on the basis of subjective response
66. American Diabetes Association, Consensus development 891–9. and early clinical improvement, J Clin Psychiatry, 1987;48:
conference on antipsychotic drugs and obesity and 88. Druss BG, Bradford WD, Rosenheck RA, et al., Quality of 363–5.
diabetes, Diabetes Care, 2004;27:596–601. medical care and excess mortality in older patients with 110.Nedopil N, Pflieger R, Ruther E, The prediction of acute
67. Azorin JM, Strub N, Loft H, A double-blind, controlled study mental disorders, Arch Gen Psychiatry, 2001;58:565–72. response, remission and general outcome of neuroleptic
of sertindole versus risperidone in the treatment of 89. Fagiolini A, Frank E, Scott JA, et al., Metabolic syndrome in treatment in acute schizophrenic patients,
moderate-to-severe schizophrenia, Int Clin Psychopharmacol, bipolar disorder: findings from the Bipolar Disorder Center Pharmacopsychiatria, 1983;16:201–5.
2006;21:49–56. for Pennsylvanians, Bipolar Disord, 2005;7:424–30. 111.Stern RG, Kahn RS, Harvey PD, et al., Early response to
68. Tamminga CA, Mack RJ, Granneman GR, et al., Sertindole 90. Frayne SM, Halanych JH, Miller DR, et al., Disparities in haloperidol treatment in chronic schizophrenia, Schizophr
in the treatment of psychosis in schizophrenia: efficacy diabetes care: impact of mental illness, Arch Intern Med, Res, 1993;10:165–71.
and safety, Int Clin Psychopharmacol, 1997;12(Suppl. 1):29–35. 2005;165:2631–8. 112.Zemlan FP, Thienhaus OJ, Garver DL, Length of psychiatric
69. Hale A, Azorin JM, Kasper S, et al., Sertindole improves 91. Newcomer JW, Rasgon N, Craft S, Insulin resistance and hospitalization and prediction of antipsychotic response,
both the positive and negative symptoms of metabolic risk during antipsychotic treatment, Presented Prog Neuropsychopharmacol Biol Psychiatry, 1990;14:13–24.
schizophrenia: results of phase III trial, Int J Psych Clin Prac, at the 158th annual meeting of the American Psychiatric 113.Correll CU, Malhotra AK, Kaushik S, et al., Early prediction
2000;4:55–62. Association, 2005, Atlanta, Georgia. of antipsychotic response in schizophrenia, Am J Psychiatry,
70. Weiden PJ, Newcomer JW, Loebel AD, et al., Long-term 92. Nasrallah HA, Meyer JM, Goff DC, et al., Low rates of 2003;160:2063–5.
changes in weight and plasma lipids during maintenance treatment for hypertension, dyslipidemia and diabetes in 114.Leucht S, Busch R, Kissling W, et al., Early prediction of
treatment with ziprasidone, Neuropsychopharmacology, schizophrenia: data from the CATIE schizophrenia trial antipsychotic nonresponse among patients with
2008;33:985–94. sample at baseline, Schizophr Res, 2006;86:15–22. schizophrenia, J Clin Psychiatry, 2007;68:352–60.
71. Rosenheck RA, Davis S, Covell N, et al., Does switching to 93. Graham I, Atar D, Borch-Johnsen K, et al., European 115.Leucht S, Shamsi SA, Busch R, et al., Predicting
a new antipsychotic improve outcomes? Data from the guidelines on cardiovascular disease prevention in clinical antipsychotic drug response, Schizophr Res, 2008;101:
CATIE Trial, Schizophr Res, 2009;107:22–5. practice: executive summary, Atherosclerosis, 2007;194: 312–19.
72. Fontaine KR, Heo M, Harrigan EP, et al., Estimating the 1–45. 116.Chang YC, Lane HY, Yang KH, et al., Optimizing early
consequences of anti-psychotic-induced weight gain on 94. De Hert M, Dekker JM, Wood D, et al., Cardiovascular prediction for antipsychotic response in schizophrenia,
health and mortality rate, Psychiatry Res, 2001;101:277–88. disease and diabetes in people with severe mental illness: J Clin Psychopharmacol, 2006;26:554–9.
73. Meyer JM, A retrospective comparison of weight, lipid, Position statement from the European Psychiatric 117.Kinon BJ, Chen L, Ascher-Svanum H, et al., Predicting
and glucose changes between risperidone- and Association (EPA), supported by the European Association response to atypical antipsychotics based on early
olanzapine-treated inpatients, J Clin Psychiatry, 2002;63: for the Study of Diabetes (EASD) and the European response in the treatment of schizophrenia, Schizophr Res,
425–33. Society of Cardiology (ESC), Eur Psychiatry, 2009; in press. 2008;102:230–40.
74. Sheitman BB, Bird PM, Binz W, et al., Olanzapine-induced 95. Haupt DW, Rosenblatt LC, Kim E, et al., Prevalence and 118.Ascher-Svanum H, Nyhuis AW, Faries DE, et al., Clinical,
elevation of plasma triglyceride levels, Am J Psychiatry, predictors of lipid and glucose monitoring in commercially functional, and economic ramifications of early
1999;156:1471–2. insured patients treated with second-generation nonresponse to antipsychotics in the naturalistic
75. Osser DN, Najarian DM, Dufresne RL, Olanzapine antipsychotic agents, Am J Psychiatry, 2009;166:345–53. treatment of schizophrenia, Schizophr Bull,
increases weight and serum triglyceride levels, J Clin 96. Morrato EH, Newcomer JW, Kamat S, et al., Metabolic 2008;34:1163–71.
Psychiatry, 1999;60:767–70. Screening after the ADA’s Consensus Statement on 119.Kinon B, Chen L, Stauffer V, et al., Predicting response to
76. Melkersson KI, Hulting AL, Brismar KE, Elevated levels of Antipsychotic Drugs and Diabetes, Diabetes Care, 2009; risperidone treatment through identification of early-onset
insulin, leptin, and blood lipids in olanzapine-treated in press. of antipsychotic drug action in schizophrenia, Schizophr
patients with schizophrenia or related psychoses, J Clin 97. Hennekens CH, Increasing burden of cardiovascular Res, 2008;102(Suppl. 2):256.
38 EUROPEAN PSYCHIATRIC REVIEW